Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 31–40, page 4 of 20. Filter these by subject, year and score in the research library →

1. Lecanemab Therapy and APOE GenotypeResearch summary

   Research summaries · alzhub.org/study/lecanemab-therapy-and-apoe-genotype-39141762

   Lecanemab, brand name Leqembi, is a monoclonal antibody that targets amyloid beta (Aβ) aggregates for the treatment of Alzheimer disease (AD) (1). It is approved by the US Food and Drug Administration (FDA) for individuals with …

2. Lecanemab: First ApprovalResearch summary

   Research summaries · alzhub.org/study/lecanemab-first-approval-36856953

   Lecanemab (lecanemab-irmb; LEQEMBI™) is a humanized immunoglobulin gamma 1 (IgG1) against aggregated soluble and insoluble forms of amyloid-β peptide. It is being developed by Eisai, under a global licence from BioArctic …

3. Lecanemab: More Questions Than Answers!Research summary

   Research summaries · alzhub.org/study/lecanemab-more-questions-than-answers-38095822

   The approval of lecanemab by the US Food and Drug Administration has been touted as a defining moment in the treatment of Alzheimer's disease. Lecanemab, an anti-amyloid beta monoclonal antibody, is the first Alzheimer's disease …

4. Lecanemab and Vascular-Amyloid Deposition in Brains of People With Down SyndromeResearch summary

   Research summaries · alzhub.org/study/lecanemab-and-vascular-amyloid-deposition-in-brains-of-people-with-39158850

   Importance Anti-β-amyloid immunotherapy using lecanemab is becoming increasingly available to patients with Alzheimer disease (AD). Individuals with Down syndrome (DS) develop AD neuropathology by age 40 years, representing a …

5. Lecanemab: Appropriate Use Recommendations by Korean Dementia AssociationResearch summary

   Research summaries · alzhub.org/study/lecanemab-appropriate-use-recommendations-by-korean-dementia-39512702

   Lecanemab (product name Leqembi®) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia …

6. Lecanemab: Looking Before We LeapResearch summary

   Research summaries · alzhub.org/study/lecanemab-looking-before-we-leap-37479527

   Lecanemab, a novel amyloid-sequestering agent, recently received accelerated Food and Drug Administration approval for the treatment of mild dementia due to Alzheimer disease (AD) and mild cognitive impairment (MCI). Approval was …

7. Practical Guide of the Korean Association for Geriatric Psychiatry to Anti-Amyloid Monoclonal Antibody Therapy for Alzheimer's Disease: Focused on LecanemabResearch summary

   Research summaries · alzhub.org/study/practical-guide-of-the-korean-association-for-geriatric-psychiatry-to-40696527

   … disease modification. Lecanemab, a humanized mAb targeting soluble Aβ protofibrils and plaque, received regulatory approval in Korea in July 2024, following global randomized controlled trial data demonstrating its efficacy to …

8. Real-world safety and efficacy of lecanemab in the treatment of Alzheimer's disease: a systematic review and meta-analysisResearch summary

   Research summaries · alzhub.org/study/real-world-safety-and-efficacy-of-lecanemab-in-the-treatment-of-42907679

   Results Thirty-seven studies were included. Baseline microhemorrhage was associated with higher any ARIA (23.4% vs 11.5%) and ARIA-H (19.3% vs 4.2%), but not ARIA-E (5.4% vs 5.7%). ARIA incidence did not differ significantly by …

9. Lecanemab (Leqembi) is not the right drug for patients with Alzheimer's diseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-leqembi-is-not-the-right-drug-for-patients-with-alzheimer-s-37676096

   … Administration (FDA) approved lecanemab (Leqembi) for the treatment of Alzheimer's dementia (AD) patients. In 2 clinical trials, lecanemab reduced amyloid in the brain and slowed cognitive decline. Here, I review in detail the …

10. Lecanemab appropriate use recommendations for clinical practice in the UKResearch summary

    Research summaries · alzhub.org/study/lecanemab-appropriate-use-recommendations-for-clinical-practice-in-41390238

    Lecanemab is an anti-amyloid monoclonal antibody, recently approved in the UK as a treatment for mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD) in adults who are apolipoprotein E ε4 gene (APOE4) …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.